**Table D-60. Evidence table for studies addressing management of PPH (Chauleur 2008b)**

|  |  |  |  |
| --- | --- | --- | --- |
| **Study**  **Description** | **Intervention** | **Inclusion/Exclusion**  **Criteria & Population** | **Outcomes** |
| Author:  Chauleur et al.,  200861  Country:  France  Enrollment period:  1996 to 2005  Birth setting:  Hospital  Facility characteristics:  Tertiary care  Funding: NR  Design:  Case series | **Intervention:**  Women with a primary PPH resistant to medical treatment who underwent uterine artery embolization or hysterectomy.  **Groups:**  **G1a:** embolization  **G1b:** hysterectomy  **G1c:** embolization & hysterectomy  N:  **G1a:** 41  **G1b:** 6  **G1c**: 5  Duration of treatment: NR  Timing of treatment: NR  Order of treatment: NR  Length of follow-up:  NR, follow-up interview in 2007 | **Operational definition of PPH:**  Greater than 500 mL  **Definition of success of treatment**: cessation of external bleeding  **Method of blood loss measurement:** collecting bag  **Severity: NR**  Inclusion criteria:   * Women with a primary PPH resistant to medical treatment who underwent uterine artery embolization or hysterectomy   Exclusion criteria: NR  **Maternal age, yrs, median (range):**  **Overall:** 27.3 (19-41)  **G1a:** 29.2 ± 4.65  **G1b:** 30.1 ± 4.11  **G1c:** 36.6 ± 4.56  **Parity, n (%):**  Primiparous  **G1a:** 9 (21.9)  **G1b:** 2 (33)  **G1c:** 0  Multiparous  **G1a:** 32 (78)  **G1b:** 4 (66)  **G1c**: 5 (100)  **Weeks gestation:** NR  **Single pregnancy, n:**  **G1a:** 36  **Multiple pregnancy, n:**  **G1a:** 10  **Race/ethnicity:** NR  **BMI:** NR  **Baseline hemoglobin:** NR  **SES:** NR  **Mode of birth, n (%):**  Unassisted vaginal delivery  **G1a:** 9 (21.9)  **G1b:** 2 (33)  **G1c**: 0  Instrumental vaginal  **G1a:** 2(4.8)  **G1b:** 0  **G1c**: 0  Cesarean  **G1a:** 30 (73.1)  **G1b:** 4 (66)  **G1c:** 5 (100)  **Risk factors, n (%):** NR  **Primary etiology of PPH, n (%):**  Atony  **G1a:** 32 (69.5)  Placenta accreta or percreta  **G1a:** 8 (17.3)  Placenta previa  **G1a:** 3 (6.5)  Placental abruption  **G1a:** 1 (2) Myoma and atony  **G1a:** 1 (2)  Parametrical dissecting hematoma  **G1a:** 1 (2)  Time between delivery & procedure, min (range)  **G1a:** 263 (90-750) | **Mortality: G1a:** 1 (treated with in situ methotrexate and died 4 months after embolization due to methotrexate-related nephrotoxicity  **Uterine preservation:**  Embolization successful, n (%)  **G1a:** 41/46 (89.1)  Five patients underwent additional procedures  1. parametrical dissecting hematoma, embolization completed by the insertion of a coil into the R uterine artery (G1c)  2. Ovarian artery embolization  3. Hypogastric artery catheterized & embolization performed beyond the gluteal artery.  4. Superselective embolization of the internal iliac artery branch  5. Embolization performed after ligation of hypogastric arteries (embolization of the residual stump of hypogastric artery & anastomatic pelvic trats).  Future fertility (data for 37/41)  No wish for further children: 16  No present wish for another child: 5  Wanted another child: 16 (39%)  Became pregnant within 1-11 months: 16/16 (100%)  Return of normal menses  **G1a:** 41 (100%)  More than 1 pregnancy after embolization: 6  Repeat PPH - 1  **Harms of intervention:**  Allergy to iodine, n  **G1a:** 1  Acute pulmonary edema, n  **G1a:** 1  Cardiovascular instability **G1a:** 1  Major hemoperitoneum related to dissection of epigastric artery (re-operated 4 times), n **G1a:** 1  **Confounders:** NR  **Effect modifiers:** NR |